Kessler Topaz Meltzer & Check, LLP: Investigation on Behalf of Annovis Bio, Inc. Shareholders

Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of Annovis Bio, Inc. ("Annovis") (NYSE American: ANVS) securities between May 6, 2021 and July 28, 2021.  

Annovis investors may receive additional information about the investigation by clicking the link "Submit Your Information" above.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The Company's lead candidate is Posiphen, an orally administered drug that purportedly inhibits the production of neurotoxic proteins that lead to neurodegeneration.

On July 28, 2021,  Annovis reported clinical trial data for Posiphen that failed to show statistical significance in treating Alzheimer's and Parkinson's Disease patients relative to a placebo.

Following this news, Annovis' stock price dropped to $65.94 per share, a decline of over 60%.

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  James Maro, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at [email protected].